pharma · Diabetes Mellitus, Type 2 · Sickle Cell Disease · CYCN
Cyclerion Therapeutics
Cyclo Therapeutics is a pharma organization headquartered in Gainesville, USA. It trades on NYSE under ticker CYCN. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Sickle Cell Disease, Achalasia. NovaP
Gainesville, USA HQ
1990 Founded
14 Employees
Public company Type
CYCN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Gainesville, USA
- Founded
- 1990
- Employees
- 14
- Programs
- 9
- Drugs
- 2
- Patents
- 17
IW-1701
Phase 2 · small molecule · Sickle Cell Disease
IW-1701 for Sickle Cell Disease is a Phase 2 program (small_molecule) at Cyclerion Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code C1701-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cyclerion Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Sickle Cell Disease
- Status
- completed
- Trials
- 1